PPARG and metabolic disease: It is easy to understand that PPARG polymorphisms in the promoter region, as well as missense polymorphisms in the exonic region, may cause metabolic disorders such as hypercholesterolemia, hypertriglyceridemia, and hyperglycemia, which subsequently increase the risk of CAD.